Standard BioTools (NASDAQ:LAB) versus Clover Health Investments (NASDAQ:CLOV) Critical Review

Standard BioTools (NASDAQ:LABGet Free Report) and Clover Health Investments (NASDAQ:CLOVGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Standard BioTools and Clover Health Investments’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Standard BioTools -86.06% -20.89% -15.98%
Clover Health Investments -3.29% -16.79% -9.95%

Analyst Recommendations

This is a breakdown of recent ratings for Standard BioTools and Clover Health Investments, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Standard BioTools 1 3 0 0 1.75
Clover Health Investments 1 3 1 0 2.00

Standard BioTools currently has a consensus target price of $1.35, indicating a potential downside of 8.78%. Clover Health Investments has a consensus target price of $3.23, indicating a potential upside of 37.01%. Given Clover Health Investments’ stronger consensus rating and higher possible upside, analysts clearly believe Clover Health Investments is more favorable than Standard BioTools.

Earnings and Valuation

This table compares Standard BioTools and Clover Health Investments”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Standard BioTools $174.43 million 3.26 -$138.88 million ($0.34) -4.35
Clover Health Investments $1.37 billion 0.89 -$43.01 million ($0.11) -21.45

Clover Health Investments has higher revenue and earnings than Standard BioTools. Clover Health Investments is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 19.8% of Clover Health Investments shares are held by institutional investors. 23.2% of Standard BioTools shares are held by insiders. Comparatively, 24.1% of Clover Health Investments shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Standard BioTools has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Clover Health Investments has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500.

Summary

Clover Health Investments beats Standard BioTools on 11 of the 14 factors compared between the two stocks.

About Standard BioTools

(Get Free Report)

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

About Clover Health Investments

(Get Free Report)

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat. Clover Health Investments, Corp. is based in Franklin, Tennessee.

Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.